United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - not applicable

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - ramipril - oral tablet - 2.5mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi-aventis s.p.a. - ramipril, hydrochlorothiazide - tablets - 5mg+ 25mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - valsartan, quantity: 25.7 mg; sacubitril, quantity: 24.3 mg - tablet, film coated - excipient ingredients: hyprolose; colloidal anhydrous silica; sodium starch glycollate type a; purified talc; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - valsartan, quantity: 25.7 mg; sacubitril, quantity: 24.3 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; purified talc; hyprolose; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 24.3 mg; valsartan, quantity: 25.7 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate; purified talc; colloidal anhydrous silica; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 24.3 mg; valsartan, quantity: 25.7 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; purified talc; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - valtresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Canada - English - Health Canada

sanofi pasteur limited - pertussis toxoid; filamentous haemagglutinin; fimbriae; pertactin; diphtheria toxoid; tetanus toxoid; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett; haemophilus influenzae type b-prp; tetanus protein - liquid - 20mcg; 20mcg; 5mcg; 3mcg; 15lf; 5lf; 40unit; 8unit; 32unit; 10mcg; 30mcg - pertussis toxoid 20mcg; filamentous haemagglutinin 20mcg; fimbriae 5mcg; pertactin 3mcg; diphtheria toxoid 15lf; tetanus toxoid 5lf; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40unit; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8unit; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32unit; haemophilus influenzae type b-prp 10mcg; tetanus protein 30mcg - vaccines

Canada - English - Health Canada

sanofi pasteur limited - pertactin; fimbriae; filamentous haemagglutinin; pertussis toxoid; tetanus protein; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney; haemophilus influenzae type b-prp; tetanus toxoid; diphtheria toxoid - suspension - 3mcg; 5mcg; 20mcg; 20mcg; 30mcg; 26unit; 7unit; 29unit; 10mcg; 5lf; 15lf - pertactin 3mcg; fimbriae 5mcg; filamentous haemagglutinin 20mcg; pertussis toxoid 20mcg; tetanus protein 30mcg; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett 26unit; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1 7unit; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney 29unit; haemophilus influenzae type b-prp 10mcg; tetanus toxoid 5lf; diphtheria toxoid 15lf